Rare but relevant: Ibogaine and cardiovascular complications—prolonged QT interval and ventricular arrhythmias
Safety (cardiac & more) Review high
AI-extracted · unverified · confirm at source
Narrative review, no new primary fatalities: QTc prolongation at therapeutic doses even without cardiac history; CYP2D6 poor metabolisers at higher risk; safe dose ~0.87 mg/kg (10× lower, may lack efficacy); recommends genotyping + monitoring.
Dosing: Safe dose ~0.87 mg/kg (10× lower than therapeutic 8–14 mg/kg) (oral)
Safety data present: QTC, HERG, ELECTROLYTE
Contraindications: QTc prolongation (≥450 ms males, ≥460 ms females), CYP2D6 poor metaboliser status (genotyping recommended), Concurrent QT-prolonging medications, Doses exceeding ~0.87 mg/kg without cardiac monitoring